Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 65

Repurposing mefloquine for diffuse intrinsic pontine glioma therapy

Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive brain tumors found in an area of the brainstem called the pons, which controls many of the body’s most vital functions such as breathing, blood pressure, and heart rate. DIPG is the leading cause of pediatric death by brain tumor. ...

Using zebrafish to accelerate DIPG drug development

A critical barrier to improvements in diffuse intrinsic pontine glioma (DIPG) therapy is a lack of new drugs that have a broad therapeutic index. In DIPG, validation of new therapeutics is hampered by the long time (6 months) that most human DIPG tumors take to kill mice. This means that it ...

Advanced RNAi therapeutics for DIPG

Diffuse intrinsic pontine glioma (DIPG) is a form of brain tumor that arises in the brainstem of children and is nearly 100% fatal with a median survival of 9-12 months after diagnostic. The location of these highly infiltrating tumors in the ventral pons precludes surgical resection and clinical trials with different ...

Short-pulse ultrasound delivery of panobinostat for the treatment of diffuse ...

Children with diffuse intrinsic pontine gliomas (DIPGs) have a 2-year survival rate of less than 10%. Compared to other brain cancers, DIPG is particularly difficult to treat because it spreads behind an intact blood-brain barrier (BBB) affecting healthy developing paediatric brain tissue. There are currently no effective treatments for this disease. ...

study of radiotherapy and concurrent bevacizumab temozolamide followed by bevacizumab. ...

Five-year overall survival in children with high-grade glioma (HGG) and diffuse, intrinsic brainstem glioma (DIPG) are  approximately 25% and 10%, respectively 1-3.  Achieving cure for all children with HGG and DIPG  remains a major goal of pediatric neuro-oncology. DIPGs are infiltrative gliomas, and have typically been found to be &...